To clarify whether NETO2 contributed to malignant progress in ESCC cells through activation of ERK and PI3K/AKT pathways, we treated ESCC cells with an ERK inhibitor SCH772984 or a PI3K inhibitor LY294002. This evidence concerns the gene NETO2 and esophageal squamous cell carcinoma.